Phoenixin-14 as a Potential Limiting Neuropeptide for Exaggerated Inflammation in Familial Mediterranean Fever and Periodic Fever, Aphthous Stomatitis, Pharyngitis, and Cervical Adenitis: A Comparative Study
Authors' conclusion
PNX-14 may be part of a neuroimmune response aimed at resolving inflammation in autoinflammatory processes and could be a potential immunomodulatory biomarker.
Study context
- Population
- Children with familial Mediterranean fever (FMF) or PFAPA and healthy children
- Participants
- 140 children
- Exposure
- FMF and PFAPA vs healthy children
- FMFn = 46
- PFAPAn = 48
- Healthy childrenn = 46reference
- Outcome
- Serum phoenixin-14 (PNX-14) levels (ELISA) during attack and attack-free periods
Methodological detailscomparative
- Comparative
Main finding
As reported in the abstract
Serum PNX-14 levels
- PNX-14 significantly higher during attack periods in FMF and PFAPA vs attack-free periods and healthy controls
- P < 0.001
- PNX-14 during attack-free periods also higher in both patient groups than in healthy controls
- P < 0.001
Observational data: associations, not effects.
Further findings
Correlation of PNX-14 with C-reactive protein (CRP)
- Positive correlation, ρ
- 0.222
- P
- P = 0.04
Correlation of PNX-14 with erythrocyte sedimentation rate (ESR), serum amyloid A (SAA), fibrinogen
- No significant correlation
PNX-14 vs disease severity (Pras score), colchicine duration and daily dose in FMF
- No significant associations
Original publication
Phoenixin-14 as a Potential Limiting Neuropeptide for Exaggerated Inflammation in Familial Mediterranean Fever and Periodic Fever, Aphthous Stomatitis, Pharyngitis, and Cervical Adenitis: A Comparative Study. J Rheumatol. Published 15 August 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →